Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Aspen Pharmacare CEO Stephen Saad. Picture: SUPPLIED
Aspen has posted a 10% rise in interim revenue, supported by growth in commercial pharmaceuticals, as well as manufacturing. The pharmaceutical group’s bottom line however took a knock, as headline earnings per share dropped 6%. Business Day TV spoke to CEO Stephen Saad for more detail.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
NEWS LEADER
WATCH: Aspen interim earning drop 6%
Business Day TV speaks to CEO Stephen Saad
Aspen has posted a 10% rise in interim revenue, supported by growth in commercial pharmaceuticals, as well as manufacturing. The pharmaceutical group’s bottom line however took a knock, as headline earnings per share dropped 6%. Business Day TV spoke to CEO Stephen Saad for more detail.
Companies in this Story
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Aspen aims to put loss-making factories to work
SA pharmas urge Pepfar to buy more African-made HIV/Aids drugs
Where SA’s best-performing fund managers are placing their bets
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.